Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide for resistant oral chronic GvHD
NCT00887263Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Mar 2009
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of budesonide in chronic graft-versus-host disease (cGVHD), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Objective Response Rate at 12 weeks. Started Mar 2009; status: completed.
02
Drugs
budesonide
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT00887263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887263.